Hippocampal Prophylactic Cranial Irradiation for Small Cell Lung Cancer

Small-cell Lung Cancer Clinical Trial

Official title:

"A Phase II Trial of Hippocampal-Sparing Cranial Irradiation (PCI) for Small-Cell Lung Cancer (SCLC)"

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01797159
• Other study ID #: J12127
• Secondary ID: NA_00078659
• Status: Completed
• Phase: N/A
• Start date: March 11, 2013
• Est. completion date: March 18, 2019

Study information

• Verified date: September 2021
• Source: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The Investigators are looking to compare standard treatment for the management of small cell lung cancer (SCLC) which is prophylactic cranial Irradiation (PCI) (shown to be very good in patient survival) with cranial sparing PCI. Although standard of care PCI is successful in patient survival it also has neurologic side-effects. The Investigators are hoping the cranial sparing PCI has the same positive survival results with the added benefit of lowering neurological side-effects.

Description:

The standard of care in management of small cell lung cancer consists of chemotherapy plus thoracic radiation followed by prophylactic cranial irradiation (PCI) based on a randomized trial that demonstrated a significant improvement in overall survival (OS) with PCI. Unfortunately radiation therapy to the brain is associated with neurocognitive toxicity, which may be at least in part related to radiation induced injury to neural progenitor cells in the hippocampus. Both human and animal data suggest an inverse relationship between radiation dose to the hippocampus and performance on neuropsychological testing. We hypothesize that hippocampal sparing PCI will allow improved performance on tests of short term memory and executive function compared to a historical control (RTOG 0212) receiving the same dose of conventional PCI. The primary objective of this study is to evaluate performance on the Hopkins Verbal Learning Test-Revised for delayed recall at 6 months following hippocampal-sparing PCI relative to the historical control. Secondary objectives are to estimate: 1) composite cognitive function following hippocampal-sparing PCI relative to the historical control and 2) the rate of metastases in the hippocampus at 2 years following hippocampal-sparing PCI. The long term goal of this research is to reduce the long term sequelae of radiation therapy for both primary and metastatic brain tumors.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 20
• Est. completion date: March 18, 2019
• Est. primary completion date: March 18, 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 100 Years

Eligibility

Inclusion Criteria:

• Patient must have newly diagnosed and confirmed small-cell lung cancer (SCLC)
• Patient must have a performance status of 1 or higher
• Patients must not have received previous irradiation to the brain
• Patients must have limited stage disease with complete response to chemotherapy and consolidative chest radiotherapy that was documented at least on standard chest x-rays within one month of study entry
• Negative MRI or CT scan of the brain at least one month before protocol entry
• Women of child-bearing potential must have a negative pregnancy test and also agree to use adequate contraceptives while on protocol
• Patient must be able to understand and sign the informed consent document
• Patient must be informed of the investigational aspect to this trial prior to singing the informed consent document

Exclusion Criteria:

• Patients receiving prior external beam irradiation to the head or neck, including any form of stereotactic irradiation
• Radiographic evidence of brain metastases and/or ipsilateral lung metastases/malignant pleural effusion
• Planned concurrent chemotherapy or antitumoral agent during PCI
• Concomitant malignancy or malignancy within the past five years other than nonmelanomatous skin cancer or carcinoma in situ of the cervix
• Patients with minimal pleural effusion evident on chest X-ray; minimal pleural effusion visible on chest CT is allowed.
• Patients with epilepsy requiring permanent oral medication
• Patients must not have a serious medical or psychiatric illness that would, in the opinion of the investigator, prevent informed consent or completion of protocol treatment, and/or follow-up visits.
• Patients may not take Memantine. This is the only eligibility criterion that has been added to those of RTOG 0212, since some physicians might now prescribe Memantine. This medication would not have been given at the time of enrollment on RTOG 0212 and its administration could confound the results of this study.

Related Conditions & MeSH terms

• Lung Neoplasms
• SCLC
• Small Cell Lung Cancer Limited Stage
• Small Cell Lung Carcinoma
• Small-cell Lung Cancer

Intervention

Radiation:
• Hippocampal-sparing Prophylactic Cranial Irradiation
Hippocampal-sparing Prophylactic Cranial Irradiation

Locations

Country	Name	City	State
United States	Bayview Medical Center	Baltimore	Maryland
United States	The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	Baltimore	Maryland

Sponsors (1)

Lead Sponsor	Collaborator
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Effect of Hippocampal-sparing Prophylactic Cranial Irradiation (PCI) on Possible Delayed Recall Toxicity as Assessed by the Hopkins Verbal Learning Test-Revised (HVLT-R) for Delayed Recall	The primary endpoint of this study is cognitive function or memory. Memory is measured by participant performance on the Hopkins Verbal Learning Test-Revised for delayed recall (HVLT-R-Delayed Recall) at 6 months following hippocampal-sparing PCI. The HVLT-Delayed minimum and Maximum scores are 0-12. A higher score means a better outcome.	Baseline, 6 months and 12 months post radiation treatment
Secondary	Compare Cognitive Function Following Sparing PCI to That of Standard PCI	Composite cognitive function following hippocampal-sparing PCI relative to a historical control receiving standard PCI.; HVLT-R Hopkins Verbal Learning Test Revised and Brief Visuospatial Memory Test-Revised (BVMT-R); Total Recall (0-36) higher = better; Delayed Recall (0-12) higher = better; Discrimination (-12 to 12) higher = better Trail Making A & B (0-300 seconds) higher = poorer Controlled Oral Word Association (COWA) (0-180) higher = better Mini-Mental State Exam (MMSE) (0-30) higher = better Perceptual Comparison Test (PCT) (0-128) higher = better Brief Test of Attention (BTA) (0-20) higher = better Calibrated Ideational Fluency Assessment (CIFA); Letter Word Fluency (0-120) higher = better; Category Word Fluency (0-120) higher = better; Verbal Fluency (0-240) higher = better Learning and Memory; Verbal Composite T score (mean = 100, standard deviation = 15), higher = better; Visual Composite T score (mean = 100, standard deviation = 15), higher = better	Baseline
Secondary	Compare Cognitive Function Following Sparing PCI to That of Standard PCI	Composite cognitive function following hippocampal-sparing PCI relative to a historical control receiving standard PCI.; HVLT-R Hopkins Verbal Learning Test Revised and Brief Visuospatial Memory Test-Revised (BVMT-R); Total Recall (0-36) higher = better; Delayed Recall (0-12) higher = better; Discrimination (-12 to 12) higher = better Trail Making A & B (0-300 seconds) higher = poorer Controlled Oral Word Association (COWA) (0-180) higher = better Mini-Mental State Exam (MMSE) (0-30) higher = better Perceptual Comparison Test (PCT) (0-128) higher = better Brief Test of Attention (BTA) (0-20) higher = better Calibrated Ideational Fluency Assessment (CIFA); Letter Word Fluency (0-120) higher = better; Category Word Fluency (0-120) higher = better; Verbal Fluency (0-240) higher = better Learning and Memory; Verbal Composite T score (mean = 100, standard deviation = 15), higher = better; Visual Composite T score (mean = 100, standard deviation = 15), higher = better	6 months post radiation treatment
Secondary	Compare Cognitive Function Following Sparing PCI to That of Standard PCI	Composite cognitive function following hippocampal-sparing PCI relative to a historical control receiving standard PCI.; HVLT-R Hopkins Verbal Learning Test Revised and Brief Visuospatial Memory Test-Revised (BVMT-R); Total Recall (0-36) higher = better; Delayed Recall (0-12) higher = better; Discrimination (-12 to 12) higher = better Trail Making A & B (0-300 seconds) higher = poorer Controlled Oral Word Association (COWA) (0-180) higher = better Mini-Mental State Exam (MMSE) (0-30) higher = better Perceptual Comparison Test (PCT) (0-128) higher = better Brief Test of Attention (BTA) (0-20) higher = better Calibrated Ideational Fluency Assessment (CIFA); Letter Word Fluency (0-120) higher = better; Category Word Fluency (0-120) higher = better; Verbal Fluency (0-240) higher = better Learning and Memory; Verbal Composite T score (mean = 100, standard deviation = 15), higher = better; Visual Composite T score (mean = 100, standard deviation = 15), higher = better	12 months post radiation treatment
Secondary	Compare Change in Quality of Life of Hippocampal-sparing PCI Treatment Outcome to Standard PCI Treatment Quality of Life Questionnaire (QLQ)-C30	Evaluate quality of life following hippocampal-sparing PCI relative to historical control receiving standard PCI. Difference between 6 months and baseline.; Questions on the Quality of Life Questionnaire (QLQ-C30) assessment are on a four-point scale from "not at all" to "very much". Raw scores are linearly converted to a 0-100 scale with higher scores reflecting higher levels of function and higher levels of symptom burden. Questions on the QLQ-C30 cover the following: Dyspnoea; Insomnia; Appetite; Constipation; Diarrhoea; Finances; Fatigue; Nausea/Vomiting; Pain; Physical Function; Role Function; Emotional Function; Cognitive Function; Social Function; Global QoL	Baseline and 6 months post radiation treatment
Secondary	Compare Change in Quality of Life of Hippocampal-sparing PCI Treatment Outcome to Standard PCI Treatment QLQ-C30	Evaluate quality of life following hippocampal-sparing PCI relative to historical control receiving standard PCI. Difference between 12 months and baseline.; Questions on the Quality of Life Questionnaire (QLQ-C30) assessment are on a four-point scale from "not at all" to "very much". Raw scores are linearly converted to a 0-100 scale with higher scores reflecting higher levels of function and higher levels of symptom burden. Questions on the QLQ-C30 cover the following: Dyspnoea; Insomnia; Appetite; Constipation; Diarrhoea; Finances; Fatigue; Nausea/Vomiting; Pain; Physical Function; Role Function; Emotional Function; Cognitive Function; Social Function; Global QoL	Baseline and 12 months post radiation treatment
Secondary	Compare Change in Quality of Life of Hippocampal-sparing PCI Treatment Outcome to Standard PCI Treatment Quality of Life Questionnaire-Brain Cancer (QLQ-BN20)	Evaluate quality of life following hippocampal-sparing PCI relative to historical control receiving standard PCI. Difference between 6 months and baseline.; Questions on the Quality of Life Questionnaire-Brain Cancer (QLQ-BN20) are rated on a four-point scale ('not at all', 'a little', 'quite a bit' and 'very much'), and are linearly transformed to a 0-100 scale. Higher scores represent more severe symptoms. Questions on the QLQ-BN20 cover the following: Headaches; Seizures; Drowsy; Hair loss; Itching; Weakness; Bladder; Future Uncertainty; Visual Disorder; Motor Dysfunction; Communication Deficit	Baseline and 6 months post radiation treatment
Secondary	Compare Change in Quality of Life of Hippocampal-sparing PCI Treatment Outcome to Standard PCI Treatment Using the Quality of Life Questionnaire-Brain Cancer (QLQ-BN20).	Evaluate quality of life following hippocampal-sparing PCI relative to historical control receiving standard PCI. Difference between 12 months and baseline.; Questions on the Quality of Life Questionnaire-Brain Cancer (QLQ-BN20) are rated on a four-point scale ('not at all', 'a little', 'quite a bit' and 'very much'), and are linearly transformed to a 0-100 scale. Higher scores represent more severe symptoms. Questions on the QLQ-BN20 cover the following: Headaches; Seizures; Drowsy; Hair loss; Itching; Weakness; Bladder; Future Uncertainty; Visual Disorder; Motor Dysfunction; Communication Deficit; Headaches Seizures Drowsy Hair loss Itching Weakness Bladder Future Uncertainty Scale Visual Disorder Scale Motor Dysfunction Scale Communication Deficit Scale	Baseline and 12 months post radiation treatment
Secondary	Number Participants With Hippocampus Brain Metastases Following Sparing PCI	The number of participants with brain metastases after sparing PCI treatment was assessed to be compared to two existing studies.	12 months
Secondary	Assess if Development of Leptomeningeal Carcinomatosis Following Sparing PCI is Higher Than Expected	Determine whether development of leptomeningeal carcinomatosis following hippocampal-sparing PCI is higher than expected.	6 months, 12 months, 18 months and 24 months post radiation treatment
Secondary	Percentage of Participants Surviving Following Hippocampal-sparing PCI	To evaluate the survival rates of study participants following hippocampal-sparing PCI.	Up to 24 months post radiation treatment